Clinical Effect of Cetuximab Combined with Chemotheraphy on Metastastic Colorectal Cancer
10.3969/j.issn.1000-8179.2010.04.012
- VernacularTitle:西妥昔单抗联合化疗初始治疗转22例移性结直肠癌的近期疗效观察
- Author:
Liping BAI
;
Zhongchen LIU
;
Zhongquan QI
;
Zhijie DING
;
Sibo YUAN
;
Shifeng ZHANG
;
Xingfeng QIU
- Publication Type:Journal Article
- Keywords:
Cetuximab;
Colorectal cancer;
Target therapy;
Combined chemotherapy
- From:
Chinese Journal of Clinical Oncology
2010;37(4):220-222
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the efficacy and the adverse reactoions of cetuximab combined with cheomotherapy (oxapliplatin or iriticon) for metastastic colorectal cancer. Methods: A total of 22 patients with metastastic colorectal cancer were treated with cetuximab combined with FOLFIRI or mFOLFOX6. The patients received cetuximab at an initial dose of 400 mg/m~2 intravenously on day 1 in the first cycle, followed by weekly infusion of 250 mg/m~2; FOLFIRI: irinotecan 180 mg/ m~2 on day 1, CF 400 mg/m~2, 5-FU bolus 400 mg/m~2, 5-FU infusion 2400 mg/m~2 over 46 hours, once every 2 weeks; mFOLF-OX6: oxaliplatin 85mg/m~2 on day 1, CF 400 mg/m~2, 5-FU bolus 400 mg/m~2, 5-FU infusion 2400 mg/m~2 over 46 hours, once every 2 weeks. The immediate response, complete response and partial response and changes in tumor marker levels were observed. Results: There were 12 PR cases, 6 SD cases, and no CR cases. The rate of (CR+PR) was 57.1% and the rate of (CR+PR+SD) was 85.7%. The adverse reactions during the theraphy were skin toxicity and neutropenia. Conclu-sion: Safe and effective for metastastic colorectal cancer, cituximab combined with oxaliplatin or irinotecan can increase the resectabiliy rate and prolong patient survival.
